Inactivated trivalent influenza vaccine (split virion), high dose
Brand: Fluzone High-Dose
PBAC's latest decision on Inactivated trivalent influenza vaccine (split virion), high dose: Noted (2019). Considered for Active immunisation against influenza disease caused by influenza virus types A and B in persons aged 65 years and older.
PBAC outcome
Noted
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2018
Submissions
2
2018 → 2019
Eligible population
Adults aged 65 years and older for active immunisation against influenza disease caused by influenza virus types A and B.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Occurrences of culture- or PCR confirmed influenza
Pivotal trial size
31,989 patients
Key trials
FIM12, Gravenstein 2017, Izurieta
Comparator
standard dose quadrivalent influenza vaccine (QIV-SD)
Economic model
Cost-minimisation
ICER note
Pricing and financial implications redacted in public summary. Document states net cost to government was projected to be $'''' million in Year 1 and $'''' million in Year 6 with claimed offset by hospitalisation savings, but no explicit ICER value is stated.
Submission history
Jul 2018: Recommended with restriction · Restricted